The
global Malignant
Lymphoma Market is anticipated to grow at a positive CAGR in the
forthcoming period. Lymphoma is a malignant disease affecting the spleen and
bone marrow and happens in the lymphatic system. Lymphoma occurs due to
abnormalities in formation of B and T lymphocytes. Lymphocytes also have the
dubious distinction of giving rise to lymphoma whilst remaining longer than
their normal term.
Lymphoma
comes under two categories namely Hodgkin and Non-Hodgkin. The lymphoma makes
its presence felt in the lymphatic system and is called Hodgkin’s lymphoma or
Hodgkin lymphoma. A swelling as a lymph node that gives a lump occur under the
skin is a symptom of lymphoma. Tests in determining the occurrence of lymphoma
comprises X-Rays or CT-Scans, lymph node biopsy, blood tests, bone marrow samples,
chest X-Ray, CT-Scan and others.
View Full Report with TOC @ https://www.millioninsights.com/industry-reports/malignant-lymphoma-market
 |
| Malignant Lymphoma Market |
NHL
or Non-Hodgkin’s lymphomas are classified into morphologic, immunco logic,
cytogenetic and molecular genetics. The side-effects of Hodgkin lymphoma
include radiation and radiation - related complaints including lung cancer,
heart disease and breast cancer. The driving factors for malignant lymphoma
market include growing incidence of lymphoma happening across the globe with US
and Canada alone accounting for nearly six million suffering from lymphoma. R
& D efforts to give growth to lymphoma market with drug discovery have come
as a major boon to market growth.
Segmentation
of malignant lymphoma market by type includes malignant lymphoma and
non-Hodgkin lymphoma. By application, the market includes chemotherapy,
radiation therapy, immunotherapy, stem cell therapy and others. Segmentation of
malignant lymphoma industry by geography includes North America, Europe, Asia
Pacific, MEA, and Latin America. North America is on top of markets with
emergence of drugs for cure of lymphoma and funds from government. Asia pacific
is depicting growth in industry because of higher incidences of lymphoma in
Asia pacific.
The
drugs for treating malignant lymphoma include Adcertis, Adriamycin, decadron,
Baycadron, Deltasone, Dexpak Taperpak, Folotyn, Solurex and Trexall. The key
players in the market in malignant Lymphoma market include Abbott Laboratories,
Eli Lilly and company, Bristol-Meyers Squibb Company, Abiogen Pharma, s.p.A and
Johnson and Johnson and Merck and Company.
Market segment by Type, Malignant
Lymphoma can be split into
•
Hodgkin Lymphoma
•
Non Hodgkin Lymphoma
Market segment by Application, Malignant
Lymphoma can be split into
•
Chemotherapy
•
Radiation Therapy
•
Immunotherapy
•
Stem Cell Therapy
Request a Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/malignant-lymphoma-market/request-sample
No comments:
Post a Comment